home / stock / aavxf / aavxf short
Short Information | Abivax SA (OTCMKTS:AAVXF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 16,346 |
Total Actual Volume | 18,154 |
Short Trends | |
---|---|
Cover Days | 2 |
Short Days | 17 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 817 |
Average Short Percentage | 85.50% |
Is there a AAVXF Short Squeeze or Breakout about to happen?
See the AAVXF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
09-08-2023 | $18.21 | $18.21 | $18.21 | $18.21 | 5,300 | 4,000 | 75.47% |
07-27-2023 | $20 | $20 | $20 | $20 | 200 | 200 | 100% |
06-12-2023 | $16.5 | $16.5 | $16.5 | $16.5 | 1,000 | 1,000 | 100% |
05-30-2023 | $18.5 | $20 | $20 | $18.5 | 700 | 700 | 100% |
04-21-2023 | $16 | $16 | $16 | $16 | 500 | 500 | 100% |
04-20-2023 | $16 | $16 | $16 | $16 | 800 | 800 | 100% |
03-20-2023 | $6.91 | $6.91 | $6.91 | $6.91 | 2,000 | 2,000 | 100% |
03-08-2023 | $0 | $7.04 | $0 | $0 | 25 | 25 | 100% |
03-06-2023 | $7.04 | $7.04 | $7.04 | $7.04 | 100 | 100 | 100% |
03-03-2023 | $7.09 | $7.09 | $7.09 | $7.09 | 1,100 | 1,100 | 100% |
02-22-2023 | $7.19 | $7.22 | $7.22 | $7.19 | 400 | 400 | 100% |
01-05-2023 | $7.12 | $7.12 | $7.12 | $7.12 | 1,600 | 1,600 | 100% |
11-11-2022 | $8.82 | $8.82 | $8.82 | $8.82 | 3,000 | 3,000 | 100% |
10-06-2022 | $0 | $9.55 | $0 | $0 | 128 | 128 | 100% |
08-22-2022 | $8.1 | $8.1 | $8.1 | $8.1 | 286 | 286 | 100% |
08-13-2021 | $31 | $30.94 | $31 | $30.92 | 359 | 140 | 39% |
07-27-2021 | $38.02 | $38.02 | $38.02 | $38.02 | 211 | 200 | 94.79% |
07-07-2021 | $34.26 | $34.26 | $34.26 | $34.26 | 115 | 6 | 5.22% |
06-16-2021 | $39 | $39 | $39 | $39 | 169 | 150 | 88.76% |
06-10-2021 | $37.26 | $37.26 | $37.26 | $37.26 | 161 | 11 | 6.83% |
News, Short Squeeze, Breakout and More Instantly...
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabi...
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients...
PARIS, FRANCE / ACCESSWIRE / October 24, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in p...